New Phase III Clinical Trials for Alzheimer’s Announced

TauRx Therapeutics Ltd has today announced that it will begin two phase III clinical trials using a drug intended to slow or stop the progression of Alzheimer’s. The drug, called LMTX™, aims to prevent the build-up of a protein called tau in the brain and will be tested in people with mild to moderate Alzheimer’s.

Tau is a protein found normally in cells, but during Alzheimer’s and other dementias it can behave abnormally and clump together to form ‘tangles’. The company state that LMTX, also called TRx0237, can help to dissolve these clumps of tau and may help to slow or stop the progression of Alzheimer’s and other dementias.

The first of the two trials will treat 833 people with mild to moderate Alzheimer’s for a year, and the second will treat 500 people with mild Alzheimer’s with LMTX for 18 months. The company has also recently announced a phase III trial using LMTX in people with frontotemporal dementia, where the build-up of tau in the brain is also a key feature.

Rebecca Wood, Chief Executive of Alzheimer’s Research UK, said:

“It is promising to see another potential new Alzheimer’s treatment moving into late stage clinical trials. While a number of other drugs in development are targeting the hallmark Alzheimer’s protein amyloid, this drug is intended to prevent the build-up of a different protein, tau. We won’t know whether the treatment has real benefits until the trials are complete, but we look forward to the results. With current Alzheimer’s drugs acting to relieve symptoms, there is a desperate need for new treatments which can slow or stop the disease.

“It takes many decades of research to get a new treatment through to the final stages of clinical testing, but with dementia research so underfunded, we risk losing the chance to capitalise on our research findings. Support for research must be maintained if we are to keep building on our knowledge and developing potential new ways to beats this devastating disease.”

These trials are not yet recruiting in the UK, but to learn more about how to get involved in research studies, you can contact DeNDRoN (Dementias & Neurodegenerative Diseases Research Network) on 0203 2064960 or visit their website.

This material has been published with the kind permission of Alzheimer Research UK.

© 2013 – 2014, City Connect News. Copyright Notice & Disclaimer are below.

Related articles:

About City Connect PR

City Connect was first established in Cambridge and aims to spread to other cities nationally and internationally in the future. City Connect’s online magazine style website reaches out to a wide audience and has something for everyone. City Connect offers a comprehensive range of features and articles, such as news, film and music reviews, trends and hot topics, dating advice, culture and style to name but a few. City Connect also holds networking events to join our writers, advertisers and readers together. City Connect events range from the casual to the formal, but everyone with a passion for networking is welcome.

Tagged . Bookmark the permalink.

Comments are closed.